Dr. Balveen Kaur is Professor and John P. and Kathrine G. McGovern Distinguished Chair within the department of Neurological surgery. She has an active research interest in translational therapeutics and is considered an expert in the field of oncolytic viral therapy. Dr. Kaur has published more than 100 manuscripts and book chapters pertaining to cancer biology, tumor microenvironment and novel therapeutics. She has a strong track record of mentoring students and post-doctoral fellows. She also serves on several national/international committees, and has been an invited chair on several NIH study sections and review panels. She is Principal Investigator/Project leader on sevral NIH grants pertaining to Neuro-oncology.


Graduate School
Biotechnology; Banaras Hindu University, Varanasi, India
Biochemistry and Molecular Biology Emory University, Atlanta, GA

Areas of Interest

Research Interests

Pre-clinical and clinical translational therapeutics for cancer therapy


Publication Information

Peer Reviewed Articles:

1. Kaur B, Avery AM and Doetsch PW.: Expression, Purification, and Characterization of Ultraviolet DNA Endonuclease from Schizosaccharomyces pombe. Biochemistry. 37(33): 11599-11604, 1998.
2. Avery AM, Kaur B, Taylor JS, Mello JA, Essigmann JM and Doetsch PW.: Substrate specificity of ultraviolet DNA Endonuclease (UVDE/Uve1p) from Schizosaccharomyces pombe. Nucleic Acids Research. 27(11): 2256-2264, 1999.
3. Kaur B, Fraser JL, Freyer G, Davey S and Doetsch PW.: A Uve1p mediated mismatch repair pathway in Schizosaccharomyces pombe. Molecular and Cellular Biology. 19(7): 4703-4710, 1999.
4. Kaur B and Doetsch PW.: Ultraviolet Damage Endonuclease (Uve1p): a Structure and Strand-Specific DNA Endonuclease. Biochemistry. 39(19): 5788-5796, 2000.
5. Majbeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG.: Geldanamycin induces degradation of HIF-1α protein via the proteosome pathway in prostate cancer cells. Cancer Research. 62(9): 2478-2482, 2002.
6. Fulci G, Nobuaki I, Daniela M, Gernert KM, Hainaut P, Kaur B, Van Meir EG.: Initiation of human astrocytoma by clonal evolution of cells with progressive loss of functions in a patient with a 283H p53 germ line mutation. Cancer Research. 62(10): 2897-905, 2002. (Featured on Cover).
7. Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir E.: Genetic and biologic progression in astrocytoma and their relation to angiogenic dysregulation. Adv. Anat. Pathol. 1(24-36), 2002.
8. Kaur B Brat DJ, Calkins CC, Van Meir E.: Brain Angiogenesis Inhibitor 1 (BAI1) is differentially expressed in the normal brain and glioblastoma independently of p53 expression. Am. J. Pathol. 162(1): 19-27, 2003.
9. Brat DJ, Kaur B, Van Meir EG. Genetic Modulation of hypoxia induced gene expression and angiogenesis: Relevance to brain tumors. Frontiers in Bioscience. 8:D100-16, 2003.
10. Brat DJ, Hunter SB, Pecot MP, Cohen C, Hammond EH, Devi NS, Kaur B, Van Meir EG.: Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and likely represent an actively migrating cell population. Cancer Research. 64(3): 920-927, 2004.
11. Kaur B, Tan C, Brat DJ, Van Meir EG.: Genetic and hypoxic regulation of angiogenesis in gliomas. J Neuro-Oncology. 70(2):229-43, 2004.
12. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, Olson JJ, Zhang Z, Van Meir EG.: Cancer Therapy with a replicating adenovirus targeting the hypoxic microenvironment of tumors. Clinical Cancer Research. 10(24): 8603-12, 2004
13. *Kaur B. Khwaja FK, Severson EA, Matheny S, Brat DJ, Van Meir EG.: Hypoxia and the HIF pathway in glioma growth and angiogenesis. Neuro-Oncology. 7(2):134-153, 2005
14. Kaur B, Brat DJ, Devi NS, Van Meir EG. Vasculostatin, a natural BAI1 proteolytic fragment is an anti-angiogenic and anti-tumorigenic factor. (2005) Oncogene 24:3632-3642.
15. Fulci G, Breymann L, Gianni D, Kurozumi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA.: Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proceedings of the National Academy of Sciences USA. 103(34): 12873-12878, 2006.
16. Cutter, JL, Kurozumi, K, Chiocca EA, Kaur, B.: Gene therapeutics: The future of brain tumor therapy? Expert Review of Anticancer Therapy 6(7):1053-64, 2006.
17. Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, Moeniralm S, Saeki Y, Carette JE, Weisledder R, Vandertop WP, Beusechem VW, Dirven CMF, Chiocca EA.: Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma bearing mice monitored by bioluminescence imaging. Molecular Therapy. 14: 779-788, 2006.
18. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Kaur B, Lawler SE, Lee RJ, Marsh CB, Brat DJ, Rooijen NV, Rachamimov AS, Weissleder R, Martuza RL, Chiocca EA.: Depletion of macrophages or microglia increases the titers of injected oncolytic viruses. Cancer Research. 67(19):9398-406, 2007.
19. Hardcastle J, Kurozumi K, Chiocca EA, Kaur B.: Oncolytic Viruses driven by tumor specific promoters. Current Cancer Drug Targets. 7(2): 181-189, 2007.
20. *Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder RW, Carson W, Chiocca EA, Kaur B.: Modulation of Tumor microenvironment to enhance Oncolytic virus therapy. Journal of National Cancer Institute. 99(23):1768-81, 2007. *Accompanied by an editorial in JNCI.
21. Kurozumi K, Hardcastle J, Thakur R, Shroll J, Chiocca EA, Kaur B.: Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates cyr61. Molecular Therapy. 16(8):1382-91, 2008.
22. Haseley A, Alvarez-Breckenridge C Chaudhury AR, Kaur B.: Advances in Oncolytic virus Therapy for Glioma. Recent Patents on CNS Drug Discovery. 4(1): 1-13, 2009.
23. Kaur B, Cork SM, Sandberg E, Devi NS, Zhang Z, Klenotic PA, Febbraio M, Shim H, Mao H, Tucker-Burden C, Silverstein RL, Brat DJ, Olson JJ, and Van Meir EG.: Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Research. 69(3):1212-20, 2009.
24. Barth RF, Kaur B.: Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. Journal of Neuro-oncology. 94(3):299-312, 2009.
25. Alvarez-Breckenridge C, Kaur B and Chiocca EA.: Pharmacologic and chemical adjuvants in tumor virotherapy. Chemical reviews 109(7): 3125-3140, 2009.
26. Kaur B, Cripe T, Chiocca EA.: “Buy one get one free:” armed viruses for the treatment of cancer cells and their microenvironment. Current Gene Therapy. 9(5):341-355, 2009.
27. Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P, Weissleder R, Chiocca EA, Kaur B.: Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Molecular Therapy 18(2): 285-294, 2010.
28. Klenotic PA, Huang P, Palomo J, Kaur B, Van Meir EG, Vogelbaum MA, Febbraio M, Gladson CL, Silverstein RL.: Histidine-rich glycoprotein modulates the anti-angiogenic effects of Vasculostatin. American Journal of Pathology 176(4):2039-50, 2010.
29. Nakashima H, Kaur B, Chiocca EA.: Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine & Growth Factor Reviews. 21(2-3):119-126, 2010.
30. Wojton J, Kaur B.: Impact of tumor microenvironment on oncolytic viral therapy.: Cytokine & Growth Factor Reviews. 21(2-3):127-134, 2010.
31. *Dmitrieva N, Yu L, Viapiano M, Chiocca EA, Cripe T, Glorioso J, Kaur B.: Choindroitinase ABC I enhances intra-tumor distribution and anti-tumor efficacy of oncolytic virus. Clinical Cancer Research. 17(6):1362-1372, 2011. *Accompanied by research highlights in Molecular therapy. PMC3140790
32. Williams SP, Nowicki MO, Liu F, Press R, Godlewski J, Abdel-Rasoul M, Kaur B, Fernandez SA, Chiocca EA Lawler SE.: Indirubins decrease glioma growth and invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Research. 71(16):5374-80, 2011.
33. Chiocca EA, Aguilar LK, Bell S, Kaur B, Hardcastle J, Cavaliere R, McGregor J, Lo S, RayChaudhuri A, Chakarvarti AG, Herbert JN, Harris KS, Grossman RG, Trask TW, Baskin DS, Monterroso CM, Manzanera AG, Aguilar-Cordova E, New PZ.: Phase Ib Study of Gene Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma. Journal of Clinical Oncology 29(27):3611-9, 2011.
34. Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang JY, Cain D, Powell K, Kaur, B.: Antitumor Efficacy of 34.5ENVE: a transcriptionally retargeted and Vstat120 expressing oncolytic virus. Molecular Therapy. 20(2):287-97, 2012.
35. Cork SM, Kaur B, Devi NS, Cooper L, Saltz JH,4, Sandberg EM, Kaluz S, Van Meir EG.: A furin/MMP-14 proteolytic cascade releases a novel 40 kDa Vasculostatin from tumor suppressor BAI1. Oncogene 13;31(50):5144-52, 2012.
36. Kaur B, Chiocca EA, Cripe TP.: Oncolytic HSV-1 virotherapy; Clinical experience and opportunities for progress. Current Pharmaceutical Biotechnology, Special Issue “Virotherapy”. 1:13(9):1842-51, 2012.
37. Alvarez-Breckenridge C, Yu J, Price R, Wei M, Wang Y, Nowicki P, Yoonhee M, Bergin S, Hwang C, Soledadad F, Kaur B, Caligiuri M, Chiocca EA.: The HDAC inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and IFNgamma generation. Journal of Virology 86(8):4566-77, 2012.
38. *Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J, Kurozumi K, Glorioso J, Caligiuri M, Kaur B.: Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Research, 72(6):1353-62, 2012. *Accompanied by research highlights in Molecular therapy.
39. Alvarez-Breckenridge C, Yu J, Kaur B, Caligiuri M, Chiocca EA.: Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Advances in Virology. doi:10.1155/2012/702839, 2012.
40. Suh S, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, Kim T, Bakacs A, Alder H, Kaur B, Aqeilan RI, Pichiorri F, Croce CM.: miR-25/32 restore p53 activity. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proceedings of the National Academy of Sciences USA. 09(14):5316-21, 2012.
41. Wurdinger T, Gatson NN, Balaj L, Kaur B, Breakefield X, Pegtel DM.: Extracellular Vesicles and the Convergence with Viral Pathways. Advances in Virology, doi: 10.1155/2012/767694, 2012.
42. Yoo JY, Pradarelli J, Haseley A, Wojton J, Kaka A, Bratasz A, Alvarez-Breckenridge C, Powell K, Pan Q, Mazar A, Teknos T, Old M, Chiocca EA, Glorioso J, Kaur B.: Copper chelation antitumor efficacy of oncolytic virus by increasing its serum stability and inhibiting angiogenesis. Clinical Cancer Research, 18(18):4931-41, 2012
43. Gatson N, Chiocca EA, Kaur B.: Anti-angiogenic Gene Therapy in the Treatment of Malignant Gliomas. Neuroscience Letters. 527(2):62-70, 2012.
44. Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, Michiue H, Chiocca EA, Kaur B, Date I.: Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology. 33(2):162-74, 2013.
45. Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, Caligiuri M, Chiocca EA.: NK cells impede glioblastoma virotherapy via NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine. 18(12):1827-34, 2012.
46. Uchida H, Marsulli M Yoo JY, Haseley A, Mazzacurati L, , Nakano K, Goins WF, Hong CS, Chan J, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, Chiocca EA, Grandi P, Cohen JB, and Glorioso JC.: Effective Treatment of Glioblastoma Using EGFR-Retargeted oHSV. Molecular Therapy. 21(3):561-9, 2013
47. Currier M, Eshun FK, Sholl A, Chernoguz, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JF, Baird WH, Haseley A, Streby KA, Wang P, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.: VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells. Molecular Therapy (5):1014-23, 2013.
48. Price RL, Song J, Bingmer K, Kim TH, Dr. Yi JY, Nowicki MO, Mo X, Hollon T, Murnan E, Alvarez-Breckenridge C, Fernandez S, Kaur B, Rivera A, Oglesbee M, Cook C, Kwon CH. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Research, 73(11):3441-50, 2013.
49. Wojton J, Chu Z, Mathsyaraja H, Meisen W, Denton N, Kwon CH, Chow LM, Palascak M, Franco R, Bourdeau T, Thornton S, Ostrowski M, Kaur B, and Qi X.: “Systemic delivery of SapC-DOPS has anti-angiogenic and antitumor effects against glioblastoma” Molecular Therapy. 21(8):1517-25, 2013.
50. Onishi M, Kurozumi K, Ichikawa T, Michiue H, Fujii K, Ishida J, Shimazu Y, Chiocca EA, Kaur B, Date i.: Gene expression profiling of the anti-glioma effect of Cilengitide. Springer Plus 15;2(1):160, 2013.
51. Stephenson JR, Paavola KJ, Schaefer SA, Kaur B, Van Meir EG, Hall RA.: Brain Specific angiogenesis Inhibitor-1 (BAI1) signaling Regulation and enrichment in the postsynaptic density. Journal of Biological Chemistry. 288(31):22248-56, 2013.
52. ¬¬Racoma IO, Meisen WH, Kaur B, Snapka RM, Wani AW.: Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. Plos One. 8(9):e72882, 2013
53. Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Chiocca EA, Kaur B, Date I.: The integrin inhibitor cilengitide enhances the anti-glioma efficacy of Vasculostatin expressing oncolytic virus. (2013) Cancer Gene Therapy 20(8):437-44. NIHMSID: 511971.
54. Chu Z, LaSance K, Blanco V, Kwon CH, Kaur B, Frederick M, Thornton S, Lemen L, Qi X.: In Vivo Optical Imaging of Brain Tumors and Arthritis Using Fluorescent SapC-DOPS Nanovesicles. Journal of Visualized Experiments. doi: 10.3791/51187, 2013.
55. Okemoto K, Wagner B, Meisen H, Haseley A, Kaur B, Chiocca EA. STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells. Plos One. 8(8):e71932. doi: 10.137, 2013.
56. Okemoto K, Kasai K, Wagner B, Haseley A, Meisen H, Bolyard C, Kaur B, Chiocca EA.: DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas Clinical Cancer Research. 19(21):5952-9, 2013.
57. Yan F, Alinari L, Lustberg M, Martin K, Cordero-Nieves, H, Banasavadi-Siddegowda, Y, Virk, S, Barnholtz-Sloan J, Hlavin Bell E, Wojton J, Jacob N, Chakravarti A, Nowicki O, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith P, Ryu J, Zhang X, Mo X, Marcucci G, Nuovo G, Kwon C, Byrd J, Chiocca EA, Li C, Sif A, Samson J, Lawler SE, Kaur B*, Baiocchi RA*.: Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma. Cancer Research 15;74(6):1752-65, 2013. * Co-corresponding
58. Yoo JY, Hurwitz B, Bolyard C, Yu J, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe T, Parris DS, Caligiuri MA, Old M, Kaur B.: Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic necroptic cell death. Clinical Cancer Research. 20(14):3787-98, 2014.
59. Kim TH, Song J, Kim SH, Parikh AK, Mo X, Palanichamy K, Kaur B, Yu J, Yoon SO, Nakano I, Kwon CH.: Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Neuro-Oncology. 16(10):1354-64, 2014.
60. Thorne AH, Meisen H, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Rich J, Puduvalli V, Yu J, Caligiuri M, Tridandapani S, Kaur B.: Role of CCN1 in macrophage mediated OV clearance. Molecular Therapy. 22(9):1678-87, 2014.
61. Kim Y, Lee HG, Dmitrieva N, Kim J, Kaur B, Friedman A.: Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti-tumor efficacy: A mathematical model. Plos One e102499. doi: 10.1371/journal.pone.0102499. eCollection, 2014.
62. Wojton J, Meisen HM, Jacob N, Thorne A, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marbarthsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B.: SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget. 5(20):9703-9, 2014.
63. Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B, Lehman NL.: Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Research 74(19):5364-70, 2014.
64. Suh S, Yoo JY, Cui R, Kaur B, Huebner K, Lee TK, Aqeilan R, Croce C.: FHIT gene Suppresses Metastasis and Epithelial-Mesenchymal Transition (EMT) in Lung Cancer through Modulation of microRNAs. PLos Genetics. 10(10):e1004652, 2014.
65. Bolyard CM, Yoo JY, Wang PY, Sainin U, Rath KS, Cripe TP, Zhang J, Selvendiran K, Kaur B.: Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Clinical Cancer Research 20(24):6479-94, 2014.
66. Meisen HW, Dubin S, Sizemore ST, Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaimie-Ramirez AC, Elder JB, Powell K, Chakravarti A, Ostrowski M, Kaur B.: Changes in BAI1 and Nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. Molecular Cancer Therapeutics 14(1):307-14, 2015.
67. Mazzacurati L, Marzilli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca N, Amankulor N, Cohen JB, Glorioso JC, Grandi P.: Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV. Molecular Therapy. 23(1):99-107, 2015.
68. Ammirati M1, Lamki T, Chitnis G, Yang X, Russell D, Coble D, Kaur B, Knopp M, Moore S, Ziaie B.: In vivo brain electrophoresis – a novel method for chemotherapy of CNS diseases. Expert Opin. Drug Delivery. 2015 Feb 10:1-8, 2015.
69. Lee TJ, Haque F, Shu D, Yoo JY, Li H, Yokel RA, Horbinski C, Kim TH, Kim SH, Kwon CH, Nakano I, Kaur B, Guo P, Croce CM.: RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget. 20;6(17):14766-76, 2015.
70. Jacobsen K, Russell L, Kaur B, Friedman A.: Effects of CCN1 and Macrophage Content on Glioma Virotherapy: A Mathematical Model. Bulletin of mathematical Biology. 77(6): 984-1012, 2015.
71. Yoo JY, Yu JG, Kaka A, Pan Q, Kumar P, Kumar B, Zhang J, Mazar A, Teknos T, Kaur B, Old M.: ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma. Molecular Therapy Oncolytics doi:10.1038/mto.2015.8, 2015.
72. Meisen HW , Wohleb ES, Jaime-Ramirez CA, Bolyard CM, Yoo JY, Russell L, Hardcastle J, Dubin S, Muili K, Yu J, Caligiuri MA, Godbout J, Kaur B.: The impact of macrophage and microglia secreted TNFα on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment. Clinical Cancer Research 15; 21(14):3274-85, 2015. Accompanied by a Comment In Neurosurgery (2015 Aug;77(2):N18-20)
73. Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso JC, Kaur B, Caligiuri MA, Yu J.: CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Sci Rep. Jul 9; 5:11483. doi: 10.1038/srep11483, 2015.
74. CanellaA, Cordero H, Sborov DW, Cascione L, Smith E, Radomska HS, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Hofmeister CC and Pichiorri F.: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget. 6(31):31134-50. doi: 10.18632/oncotarget.5290, 2015.
75. Cheng C, Ru P, Geng F, Liu J, Wu X, Cheng X, Euthine V, Hu P, Guo JY, Lefai E, Kaur B, Nohturfft A, Ma J, Chakravarti A, Guo D.: Glucose-mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth. Cancer Cell. 28(5):569-81, 2015.
76. Han J, Chen X, Chu J, Xu B, Meisen WH, Chen L, Zhang L, Zhang J, He X, Wang QE, Chiocca EA, Kaur B, Caligiuri MA, Yu J.: TGF-β treatment enhances glioblastoma virotherapy by inhibiting the innate immune response. Cancer Research. 75(24):5273-82, 2015.
77. Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE.: Standardized orthotopic xenografts in zebrafish reveal glioma cell line specific characteristics and tumor cell heterogeneity. Dis Model Mech. Dec 10. pii: dmm.022921, 2015.
78. Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter YS, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd J, Baiocchi R, Kaur B, Hofmeister CC, and Pichiorri F.: Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Molecular Cancer Therapeutics. 15(5):830-41. doi: 10.1158/1535-7163.MCT-15-0240-T, 2016.
79. Wojton J, Meisen WH, Kaur B.: How to Train Your Glioma Cells to Die: Molecular Challenges in Cell Death. Journal of Neuro-Oncology. 126(3):377-84, 2016. * Figure selected for cover.
80. Old M, Wise-Draper T, Wright CL, Kaur B, Teknos T.: The current status of oncolytic viral therapy for head and neck cancer. World Journal of Otolaryngology-Head and Neck Surgery. 2(2):84-89, 2016.
81. Barth RF, Wu G, Meisen WH, Nakkula RJ, Yang W, Huo T, Kellough DA, Kaumaya P, Turro C, Agius L, Kaur B.: Design synthesis and evaluation of cisplatin containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors. Oncotargets and Therapy 2016 9:2769-81. doi: 10.2147/OTT.S99242, 2016.
82. Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, Chen L, Wang Y, Wang H, Yi L, Elder BJ, Wang Q-E, He X, Kaur B, Chiocca EA, Yu J.: A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 7(19):27764-77. doi: 10.18632/oncotarget.8526, 2016.
83. Quispe CNE, Vicetti Miquel RD, Boyaka PN, Hall-Stoodley L, Kaur B, Trout W, Pavelko SD, Cherpes TL.: Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection. Mucosal Immunology. 9(6):1571-1583. doi: 10.1038/mi.2016.22, 2016.
84. Bhallamudi YP, Xue R, Purser CM, PresleyKF, Banasavadi-Siddegowda YK, Hwang, J, Kaur B, Hammel C, Poirier MG, Lannutti JJ, Pandian RP.: .DNanofiber based paramagnetic probes for rapid real time oximetry. Biomedical Microdevices. 18(2):38. doi: 10.1007/s10544-016-0063-1, 2016.
85. Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, Mo X, Ru P, Hurwitz B, Kim S, Otero J, Puduvalli VK, Lefai E, Ma J, Nakano I, Horbinski C, Kaur B, Chakravarti A, Guo D.: Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis. Clinical Cancer Research. 22(21):5337-5348, 2016
86. Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, Hurwitz B, Relation T, Yu JG, Lee TJ, Lotze MT, Zhang J, Croce C, Yu J, Caligiuri MA, Old M, Kaur B.: Bortezomib treatment sensitizes oncolytic HSV-1 treated tumors to NK cell immunotherapy. Clinical Cancer Research. 22(21):5265-5276, 2016. Featured on Cover. Accompanied by a Comment in Clinical Cancer research (2016 Nov 1;22(21):5164-5166)
87. Banasavadi-Siddegowda YK, Russell L, Zhang J, Karkhanis VA, Imitola J, Baiocchi R, Kaur B.: PRMT5-PTEN molecular pathway regulates senescence and self-renewal of Glioblastoma stem-like cells. Oncogene 36, 263–274, 2017.
88. Kesanakurti D, Maddirela D, Banasavadi-Siddegowda YK, Lai TH, Qamri Z, Jacob NK, Sampath D, Mohanam S, Kaur B, Puduvalli VK.: A Novel Interaction of PAK4 with PPARγ to Regulate Nox1 and Radiation-Induced Epithelial-to-Mesenchymal Transition in Glioma. Oncogene. doi: 10.1038/onc.2016.261. [Epub ahead of print], 2017
89. Lee TJ, Yoo JY, Shu D, Li H, Zhang J, Yu J, Jaime-Ramirez A, Acunzo M, Romano G, Cui R, Sun HL, Luo Z, Old M, Kaur B, Guo P, Croce CM.: RNA nanoparticle based targeted therapy for glioblastoma through inhibition of oncogenic miR-21. Molecular Therapy. pii: S1525-0016(16)45424-9. doi: 10.1016/j.ymthe.2016.11.016. [Epub ahead of print], 2017
90. Alena Jaime-Ramirez C, Dmitrieva N, Yoo JY, Banasavadi-Siddegowda Y, Zhang J, Relation T, Bolyard-Blessing C, Wojton J, Kaur B.: Humanized Chondroitinase ABC Sensitizes Glioblastoma Cells to Temozolomide. Journal of Gene medicine. Mar;19(3). doi: 10.1002/jgm.2942, 2017.
91. Jaime-Ramirez AC, Yu JG, Caserta E, Yoo JY, Zhang J, Lee TJ, Hofmeister C, Lee JH, Kumar B, Pan Q, Kumar P, Baiocchi R, Teknos T, Pichiorri F, Kaur B, Old M.: Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma Molecular Therapy Oncolytics. published online May 19, 2017.
92. Bolyard C, Meisen WH, Banasavadi-Siddegowda Y, Hardcastle J, Yoo JY, Wohleb ES, Wojton J, Yu J, Dubin S, Khosla M, Xu B, Smith J, Alvarez-Breckenridge C, Pow-anpongkul P, Pichiorri F, Zhang J, Old M, Zhu D, Van Meir EG, Godbout J, Caligiuri MA, Yu J, Kaur B.: BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection- implications for Oncolytic Viral Therapy. Clinical Cancer Research. 23(7):1809-1819, 2017.
93. Saini U, Naidu S, Elnaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K.: Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastases: a potential therapeutic target. Oncogene. 12;36(2):168-181, 2017.
94. Ru P, Hu P, Geng F, Mo X, Cheng C, Yoo JY, Cheng X, Wu X, Guo JY, Nakano I, Lefai E, Kaur B, Chakravarti A, Guo D*.: Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-driven Glioblastoma Growth. Cell Reports 16(6):1527-35. doi: 10.1016/j.celrep.2016.07.017, 2017.
95. Jaime-Ramirez AC, Yu JG, Caserta E, Yoo JY, Zhang J, Lee TJ, Hofmeister C, Lee JH, Kumar B, Pan Q, Kumar P, Baiocchi R, Teknos T, Pichiorri F, Kaur B, Old M. Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. (2017) Molecular Therapy Oncolytics. DOI:
96. Canella A, Welker AM, Yoo JY, Xu J, Abbas FS, Kesanakurti D, Nagarajan P, Beattie CE, Sulman EP, Liu JL, Gumin J, Lang FF, Gurcan M, Kaur B, Sampath D, Puduvalli VK. Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. (2017) Clinical Cancer research. clincanres.3151.2016. doi: 10.1158/1078-0432.CCR-16-3151. [Epub ahead of print]
97. Dai HS, Griffin N, Bolyard C, Mao HC, Zhang J, Cripe TP, Suenaga T, Arase H, Nakano I, Chiocca EA, Kaur B, Yu J, Caligiuri MA. The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. (2017) Immunity. 18;47(1):159-170.e10. doi: 10.1016/j.immuni.2017.06.019.
Invited Articles (Reviews, Editorials, etc.) in Journals
98. Kaur B, Chiocca EA.: Extreme treatment for an extreme disease. Future Microbiology. 1(4):351-353, 2006.
99. Kaur B, Chiocca EA. Personalizing Oncolytic Virotherapy. (2007) Molecular Therapy. 15(1):6-7.
100. Meisen H, Kaur B. How can we trick the immune system to overcome the detrimental effects of oncolytic viral therapy to treat glioblastoma? (2013) Expert Review of Neurotherapeutics. 13(4):341-343. doi: 10.1 Development of Therapeutic agents Handbook586/ern.13.25.
101. Wojton J, Elder B, Kaur B. How efficient are autophagy inhibitors as treatment for glioblastoma? 3(1) 5-7. (2014) CNS Oncology.
102. Russell L, Bolyard C, Banasavadi-Siddegowda Y, Weiss A, Zhang J, Shakya R, Powell K, Kaur B. Sex as a biological variable in response to temozolomide. (2017) Neuro-Oncology

Book Chapters: 

103. Barth R, Kaur B.: Immunocompetent intracranial Rat glioma models for preclinical therapeutic evaluations of novel therapies. In CNS Cancer. ISBN: 978-1-60327-552-1, 2009. Editor: Erwin Van-meir. Publisher: Springer.
104. Lee TJ, Haque F, Vieweger M, Yoo JY, Kaur B, Guo P, Croce CM.: Functional Assays for Specific Targeting and Delivery of RNA Nanoparticles to Brain Tumor. Methods in Molecular Biology. RNA nanotechnology and therapeutics. doi: 10.1007/978-1-4939-2562-9_10., 2015. © Springer Science+Business Media New York 2015
105. Kaur B, Lesinsky G, Choudhary A.: From Concept to the Clinics: Development of Novel Large Molecule Cancer Therapeutics. Pharmaceutical Sciences Encyclopedia. DOI: 10.1002/9780470571224.pse402. 4:1-39, 2010. Editors; Shayne C. Gad. Publisher: John Wiley & Sons. DOI: 10.1002/9780470571224.pse402
106. Price R, Kaur B, Chiocca EA.: Herpes Simplex Virus 1 for Cancer Therapy. In Gene-Based Therapies for Cancer. Current Cancer Research Book Series. DOI: 10.1007/978-1-4419-6102-0_12, 2010. Editor: Jack A Roth. Publisher: Springer, New York.